Form 4: Director David Roberts Acquires Shares in Anteris

Director David B. Roberts has acquired 17,580 shares of Anteris Technologies Global Corp. following the vesting of restricted stock units.

Summary

• David B. Roberts, a Director at Anteris Technologies Global Corp., converted 17,580 restricted stock units (RSUs) into common stock on June 7, 2026.
• The conversion was a one-for-one exchange with no exercise price paid.
• This transaction represents the first of three approximately equal installments from a grant of 52,742 RSUs originally issued on December 3, 2025.
• Following this transaction, Roberts directly owns 17,580 shares of common stock and holds 35,162 remaining unvested RSUs.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it demonstrates a director increasing their direct share ownership without immediate divestment.

Positives

• The director has retained the full amount of shares acquired through the vesting, rather than selling them immediately.
• The transaction confirms the director's continued service and alignment with the company's long-term performance.
• The vesting schedule ensures the director remains incentivized through at least June 2028.

Negatives

• The issuance of new shares upon RSU conversion results in a minor dilution of existing shareholder equity.

Risks

• Future market pressure could occur if the reporting person decides to sell shares to cover tax liabilities associated with the vesting.
• The remaining 35,162 RSUs are subject to continued service, posing a retention risk if leadership changes occur.

Future Outlook

The reporting person is scheduled to vest in two additional tranches of approximately 17,581 shares each in June 2027 and June 2028, provided they remain in service with the company.

Management Comments

• Each restricted stock unit converts into a share of common stock on a one-for-one basis.
• RSUs generally vest in approximately equal installments subject to the Reporting Person's continued service through each vesting date.

Industry Context

StockSavvy.ai notes that equity-based compensation is a standard practice in the biotechnology and medical device sectors to preserve cash while aligning the interests of board members with those of shareholders.

Comparison to Industry Standards

• The three-year vesting period is consistent with standard corporate governance practices for mid-cap medical technology companies.
• The use of RSUs instead of stock options is increasingly common among peers to reduce extreme volatility in executive compensation packages.

Stakeholder Impact

• Shareholders may view the director's increased direct stake as a sign of confidence in the company's trajectory.
• The company's share count increases slightly, marginally impacting earnings per share calculations.

Next Steps

• Monitor for any subsequent Form 4 filings that might indicate the sale of these newly acquired shares.
• Track the next vesting milestone scheduled for June 7, 2027.

Key Dates

Recommendation

This is a routine vesting event that does not signal a change in company fundamentals or a shift in insider sentiment, warranting a maintained position.

Keywords

Anteris Technologies, AVR, Insider Trading, Form 4, Restricted Stock Units, David Roberts, Executive Compensation, Medical Technology